Research Article
CTLA4 Polymorphisms and De Novo Malignancy Risk after Renal Transplantation in Chinese Recipients
Table 1
Comparison of clinical characteristics between patients with tumor and nontumor.
| Characteristic | Patients with tumor () | Patients with nontumor () | P value |
| Mean age ± SD | 40.717 ± 9.474 | 40.175 ± 10.100 | 0.712 | Sex | | | | Male | 35 (66.04) | 253 (61.56) | 0.552
| Female | 18 (33.96) | 158 (38.44) | Primary diseases | | | | Chronic glomerulonephritis | 47 (88.68) | 377 (91.73) | 0.458 | Polycystic kidney | 1 (1.89) | 17 (4.14) | 0.426 | Pyelonephritis | 2 (3.77) | 14 (3.40) | 0.891 | Aristolochic acid nephropathy | 3 (5.66) | 3 (0.73) | 0.003 | Dialysis time (≥3 years) | 23 | 193 | 0.625 | Number of HLA-mismatch | 2.57 ± 1.029 | 2.47 ± 0.806 | 0.514 | Real transplantation | | | | Living/cadaver | 5/48 | 46/365 | 0.819 | Antibody induction therapy | 17 | 140 | 0.774 | Immunosuppressant regimens | | | | CsA + MMF + Pred | 34 (64.15) | 272 (66.18) | 0.760 | TAC + MMF + Pred | 19 (35.85) | 139 (33.82) | Blood transfusion | 5 | 52 | 0.658 | Rejection | | | | AR/non-AR | 11/42 | 53/358 | 0.137 |
|
|
CsA: cyclosporine, MMF: mycophenolate mofetil, Pred: prednisone, TAC: tacrolimus, AR: acute rejection, non-AR: nonacute rejection, and tumor: drug induced liver injury.
|